Dr. William T. Ko, M.D.
Dermatology (Dermatology Physician)
2224 W Northern Ave Ste D300
Phoenix, AZ 85021
Who else practices at this address →
Maricopa County includes primary care (13% of residents) and dental (0% of residents) and mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Northeastern Ohio University College of Medicine (1994)
- Years since graduation
- 32
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 780
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1994Medical school: Northeastern Ohio University College of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Dermatology Physician primary
AZ license 26333 -
MOHS-Micrographic Surgery Physician
AZ license 26333 -
Procedural Dermatology Physician
AZ license 26333
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Center for Dermatology PLLC (71 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 780
- Services billed
- 26,057
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg | 19,800 | 88 |
| Destruction of precancer skin growth, 2-14 growths | 4,639 | 574 |
| Established patient office or other outpatient visit, 20-29 minutes | 1,168 | 698 |
| Destruction of precancer skin growth, 1 growth | 1,115 | 638 |
| Biopsy of related skin growth, first growth | 715 | 476 |
| Biopsy of related skin growth, each additional growth | 696 | 316 |
| Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, 1-5 tissue blocks | 336 | 232 |
| Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, each additional stage, 1-5 tissue blocks | 252 | 158 |
| Complicated repair of wound of forehead, cheeks, chin, mouth, neck, underarms, genitals, hands, or feet, 2.6-7.5 cm | 166 | 131 |
| Established patient office or other outpatient visit, 30-39 minutes | 157 | 123 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Mupirocin Other prescribers in Phoenix, AZ | 484 |
| Ketoconazole Other prescribers in Phoenix, AZ | 115 |
| Valacyclovir (valacyclovir hcl) Other prescribers in Phoenix, AZ | 84 |
| Fluticasone Propionate Other prescribers in Phoenix, AZ | 79 |
| Imiquimod | 67 |
| Triamcinolone Acetonide Other prescribers in Phoenix, AZ | 62 |
| Fluorouracil Other prescribers in Phoenix, AZ | 52 |
| Gentamicin Sulfate Other prescribers in Phoenix, AZ | 38 |
| Doxycycline Hyclate Other prescribers in Phoenix, AZ | 32 |
| Clobetasol Propionate Other prescribers in Phoenix, AZ | 26 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 25 companies reported 151 payments worth $3,145 in total to this clinician.
| Amgen Inc. | $477 |
|---|---|
| Leo Pharma Inc. | $381 |
| AbbVie Inc. | $361 |
| Janssen Biotech, Inc. | $254 |
| Regeneron Healthcare Solutions, Inc. | $252 |
| Novartis Pharmaceuticals Corporation | $199 |
| Pfizer Inc. | $177 |
| Organon LLC | $153 |
| Food and Beverage | $3,145 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 1 companies. The companies reported $3,620 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
AbbVie Inc. · Active, not recruiting · NCT03568318 - M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.